Company profile
IMMUNOCORE HOLDINGS PLC
NASDAQ:IMCRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| KIMMTRAK | approved | — | 0 | — |
| TEBENTAFUSP | phase3 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02570308 | phase1_2 | completed | 2016-02-29 | 2020-03-20 | Immunocore Ltd | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma |
| NCT06112314 | phase3 | recruiting | 2024-06-05 | 2027-10-16 | Immunocore Ltd | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
| NCT02889861 | phase2 | terminated | 2017-01-11 | 2019-04-22 | Immunocore Ltd | IMCgp100-401 Rollover Study |
| NCT06840119 | phase1_2 | recruiting | 2024-01-10 | 2026-11-30 | Immunocore Ltd | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers |
| NCT02535078 | phase1_2 | withdrawn | 2015-11-01 | 2023-06-19 | Immunocore Ltd | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761228 | 2022-01-25 | BLA | IMMUNOCORE LIMITED | |||||
Loading… | ||||||||